Novi, MI – According to filings with the U.S. Securities and Exchange Commission, MDI Therapeutics is raising $9,685,855.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Stephen Benoit played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About MDI Therapeutics
MDI Therapeutics is a discovery stage company focused on developing novel therapies for fibrotic diseases. By harnessing the potential of serpin biology, we aim to prevent fibrosis and even reverse the fibrotic disease process. Our scientific approach is to intercept the biological processes of the fibrin fibrotic matrix, the common denominator of all fibrotic disorders. We have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments using clinical biomarkers. We have assembled a management team with a combination of drug development and world-renown basic research expertise in serpin biology. MDI Therapeutics is therefore positioned to be the global leader in developing novel therapeutics for fibrotic diseases by targeting this critical protein family.

To learn more about MDI Therapeutics, visit http://mditherapeutics.com/

Contact:
Stephen Benoit, President and Chief Executive Officer
269-370-0775
https://www.linkedin.com/in/stephenbenoit/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved